EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SinoMab BioScience's enterprise value is HK$2,246.32 Mil.
SinoMab BioScience's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-258.71 Mil. Therefore, SinoMab BioScience's EV-to-EBITDA for today is -8.68.
The historical rank and industry rank for SinoMab BioScience's EV-to-EBITDA or its related term are showing as below:
HKSE:03681'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.04 Med: -5.05 Max: -2.29
Current: -8.6
During the past 7 years, the highest EV-to-EBITDA of SinoMab BioScience was -2.29. The lowest was -10.04. And the median was -5.05.
HKSE:03681's EV-to-EBITDA is ranked worse than 100% of 451
companies
in the Biotechnology industry
Industry Median: 9.54
vs HKSE:03681: -8.60
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
SinoMab BioScience EV-to-EBITDA Historical Data
The historical data trend for SinoMab BioScience's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SinoMab BioScience's EV-to-EBITDA
For the Biotechnology subindustry, SinoMab BioScience's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SinoMab BioScience's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SinoMab BioScience's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SinoMab BioScience's EV-to-EBITDA falls into.
SinoMab BioScience's current Enterprise Value is HK$2,246.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SinoMab BioScience's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-258.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
SinoMab BioScience's PE Ratio for today is calculated as:
SinoMab BioScience's share price for today is HK$1.76.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SinoMab BioScience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.262.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of SinoMab BioScience's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
SinoMab BioScience (HKSE:03681) Business Description
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:03681 has been successfully added to your 